Forecasting The Future: 16 Analyst Projections For argenx
Ratings for argenx (NASDAQ:ARGX) were provided by 16 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 9 | 2 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 3 | 1 | 0 | 0 |
| 2M Ago | 2 | 2 | 0 | 0 | 0 |
| 3M Ago | 1 | 3 | 1 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $1066.06, with a high estimate of $1317.00 and a low estimate of $858.00. This upward trend is evident, with the current average reflecting a 2.38% increase from the previous average price target of $1041.31.
Decoding Analyst Ratings: A Detailed Look
A clear picture of argenx's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| David Nierengarten | Wedbush | Maintains | Outperform | $1000.00 | $1000.00 |
| Luca Issi | RBC Capital | Lowers | Outperform | $890.00 | $925.00 |
| Derek Archila | Wells Fargo | Lowers | Overweight | $1247.00 | $1317.00 |
| Jason N. Butler | Citizens | Raises | Market Outperform | $944.00 | $925.00 |
| Yatin Suneja | Guggenheim | Lowers | Buy | $1120.00 | $1160.00 |
| Colleen Kusy | Baird | Raises | Neutral | $867.00 | $858.00 |
| Douglas Tsao | HC Wainwright & Co. | Raises | Buy | $940.00 | $915.00 |
| Derek Archila | Wells Fargo | Raises | Overweight | $1317.00 | $1264.00 |
| David Nierengarten | Wedbush | Maintains | Outperform | $1000.00 | $1000.00 |
| Samantha Semenkow | Citigroup | Lowers | Buy | $1091.00 | $1124.00 |
| Joon Lee | Truist Securities | Raises | Buy | $1030.00 | $950.00 |
| Colleen Kusy | Baird | Lowers | Neutral | $858.00 | $924.00 |
| Luca Issi | RBC Capital | Raises | Outperform | $925.00 | $860.00 |
| Derek Archila | Wells Fargo | Lowers | Overweight | $1264.00 | $1316.00 |
| Derek Archila | Wells Fargo | Raises | Overweight | $1316.00 | $1095.00 |
| Alex Thompson | Stifel | Raises | Buy | $1248.00 | $1028.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to argenx. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of argenx compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for argenx's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
To gain a panoramic view of argenx's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on argenx analyst ratings.
About argenx
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
argenx's Financial Performance
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: argenx's remarkable performance in 3M is evident. As of 31 December, 2025, the company achieved an impressive revenue growth rate of 14.09%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: argenx's net margin is impressive, surpassing industry averages. With a net margin of 41.45%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): argenx's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.28% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): argenx's ROA stands out, surpassing industry averages. With an impressive ROA of 6.14%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: argenx's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyst Ratings: Simplified
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.